Lucia Taramasso1,2, Marco Berruti3, Federica Briano3, Antonio Di Biagio3. 1. Infectious Diseases Unit, Department of Internal Medicine, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan. 2. MultidisciplinAry ResearCh in Health Science (MACH), Milan. 3. Infectious Diseases Clinic, Policlinico San Martino Hospital, Department of Health Sciences (DISSAL), University of Genoa, Genova, Italy.
Abstract
OBJECTIVE: To investigate whether the switch from tenofovir disoproxil fumarate/emtricitabine/rilpivirine (TDF/FTC/RPV) to tenofovir alafenamide (TAF)/FTC/RPV is associated with weight gain in people living with HIV (PLWHIV). DESIGN: Retrospective single-centre study. METHODS: All PLWHIV on TDF/FTC/RPV who switched to TAF/FTC/RPV from January 2017 to December 2018 were considered if they had at least two weight measures in the year before and two after the switch. The weight trend across the study was evaluated by a generalized linear model for repeated measures, with pair comparison performed by Bonferroni adjustment. RESULTS: Two hundred and fifty-two patients on TDF/FTC/RPV were included, 65% men, mean age 51.2 years (±9.6), history of 18 (±18.2) years of HIV infection and CD4 T-cell count of 744 (±329) cells/μl. All had HIV-RNA <50 copies/ml. Twelve months before the switch, baseline weight was 73.8 (±14.3) kg, and remained stable to 73.8 (±14.3) kg in the following 6 months. A weight increase was noticed 3 and 6 months after the switch, to 77.7 (±42.3) and 75.5 (±14.5) kg, respectively (P < 0.0001). A significant weight change exactly within the timeframe of the switch (between 6 months before and 3 months after) was found in women, patients with higher BMI (>25 kg/m), lower CD4 T-cell count (≤500 cells/μl) and history of previous drug abuse. The frequency of BMI greater than 25 kg/m rose from 122/252 patients (48.4%), to 133/252 (52.8%) (P < 0.0001). CONCLUSION: TAF appears to have an impact on weight gain, similarly to what observed in naïve patients, also in experienced PLWHIV with good virologic control.
OBJECTIVE: To investigate whether the switch from tenofovir disoproxil fumarate/emtricitabine/rilpivirine (TDF/FTC/RPV) to tenofovir alafenamide (TAF)/FTC/RPV is associated with weight gain in people living with HIV (PLWHIV). DESIGN: Retrospective single-centre study. METHODS: All PLWHIV on TDF/FTC/RPV who switched to TAF/FTC/RPV from January 2017 to December 2018 were considered if they had at least two weight measures in the year before and two after the switch. The weight trend across the study was evaluated by a generalized linear model for repeated measures, with pair comparison performed by Bonferroni adjustment. RESULTS: Two hundred and fifty-two patients on TDF/FTC/RPV were included, 65% men, mean age 51.2 years (±9.6), history of 18 (±18.2) years of HIV infection and CD4 T-cell count of 744 (±329) cells/μl. All had HIV-RNA <50 copies/ml. Twelve months before the switch, baseline weight was 73.8 (±14.3) kg, and remained stable to 73.8 (±14.3) kg in the following 6 months. A weight increase was noticed 3 and 6 months after the switch, to 77.7 (±42.3) and 75.5 (±14.5) kg, respectively (P < 0.0001). A significant weight change exactly within the timeframe of the switch (between 6 months before and 3 months after) was found in women, patients with higher BMI (>25 kg/m), lower CD4 T-cell count (≤500 cells/μl) and history of previous drug abuse. The frequency of BMI greater than 25 kg/m rose from 122/252 patients (48.4%), to 133/252 (52.8%) (P < 0.0001). CONCLUSION: TAF appears to have an impact on weight gain, similarly to what observed in naïve patients, also in experienced PLWHIV with good virologic control.
Authors: Cecile D Lahiri; Yanxun Xu; Kunbo Wang; Jessica A Alvarez; Anandi N Sheth; Jane O'Halloran; Amanda B Spence; Phyllis Tien; Deborah R Gustafson; Joel Milam; Margaret A Fischl; Deborah Konkle-Parker; Adaora A Adimora; Anjali Sharma; Kathleen M Weber; Igho Ofotokun; Leah H Rubin Journal: AIDS Res Hum Retroviruses Date: 2021-01-12 Impact factor: 1.723
Authors: Lucia Taramasso; Paolo Bonfanti; Elena Ricci; Giancarlo Orofino; Nicola Squillace; Barbara Menzaghi; Giuseppe Vittorio De Socio; Giordano Madeddu; Giovanni Francesco Pellicanò; Layla Pagnucco; Benedetto Maurizio Celesia; Leonardo Calza; Federico Conti; Canio Vito Martinelli; Laura Valsecchi; Antonio Cascio; Cesare Bolla; Paolo Maggi; Francesca Vichi; Chiara Dentone; Goffredo Angioni; Antonio Mastroianni; Katia Falasca; Giovanni Cenderello; Antonio Di Biagio Journal: Open Forum Infect Dis Date: 2020-05-26 Impact factor: 3.835
Authors: Patrick Wg Mallon; Laurence Brunet; Ricky K Hsu; Jennifer S Fusco; Karam C Mounzer; Girish Prajapati; Andrew P Beyer; Michael B Wohlfeiler; Gregory P Fusco Journal: J Int AIDS Soc Date: 2021-04 Impact factor: 5.396
Authors: Bruno Emond; Carmine Rossi; Aurélie Côté-Sergent; Keith Dunn; Patrick Lefebvre; Marie-Hélène Lafeuille; Prina Donga Journal: J Health Econ Outcomes Res Date: 2021-06-14
Authors: Rachel N Goldberg; Alexandra T Kania; Sarah M Michienzi; Mahesh Patel; Melissa E Badowski Journal: J Int Assoc Provid AIDS Care Date: 2021 Jan-Dec